FDA approves breakthrough pancreatic cancer treatment

Regulatory Approvals & Clinical Breakthroughs - The Food and Drug Administration (FDA) approved a new treatment for advanced pancreatic cancer, significantly extending patient survival [1] - The novel once-daily pill, named Rasen Q, effectively targets and turns off gene mutations that cause uncontrolled cancer cell growth [1][2] Market Potential & Therapeutic Impact - The new therapy nearly doubles the average patient survival time to 13 months, compared to approximately 7 months achieved by standard chemotherapy [1] - The treatment is specifically indicated for patients whose cancer has metastasized to other parts of the body and who have previously undergone standard treatments [2] - The medical application shows potential implications and future expansion for treating other types of cancers that share the same specific gene mutation [2]